Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
Lauren I MadiganPhuong DinhJ Dinny GrahamPublished in: Breast cancer research : BCR (2020)
This study reveals that in appropriately selected patients, NET can provide equivalent clinical benefit to neoadjuvant chemotherapy in the same cohort, if suitable treatments and durations are chosen. Our findings highlight the need for better defined biomarkers both for guiding patient selection and for measuring outcomes. Development of standard guidelines for the prescribing of NET has the potential to improve both clinical outcomes and quality of life in this patient cohort.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- postmenopausal women
- rectal cancer
- case report
- positive breast cancer
- squamous cell carcinoma
- lymph node
- radiation therapy
- bone mineral density
- phase ii study
- end stage renal disease
- sentinel lymph node
- ejection fraction
- primary care
- peritoneal dialysis
- newly diagnosed
- clinical practice
- emergency department
- prognostic factors
- estrogen receptor
- clinical trial
- body composition
- type diabetes
- adipose tissue
- combination therapy
- bone marrow
- drug induced
- study protocol
- patient reported